Table 5 Baseline characteristics of 137 BAV patients in the validation cohort
Variable | Validation cohort n = 137 | Patients without mutation n = 50 | Patients with mutation n = 87 | P value |
|---|---|---|---|---|
Gender | 76 (55.4%) | 29 (58%) | 47 (54%) | 0.652 |
Age | 64.6 ± 10.8 | 64.4 ± 12.2 | 64.7 ± 10.1 | 0.862 |
Hypertension | 50 (37.3%) | 17 (34%) | 33 (37.9%) | 0.645 |
Diabetes | 36 (26.3%) | 11 (22%) | 25 (28.7%) | 0.389 |
Hyperlipemia | 12 (8.8%) | 29 (58%) | 41 (47.1%) | 0.251 |
LVEF (%) | 60.4 ± 6.7 | 63.8 ± 7.5 | 58.4 ± 5.2 | < 0.001 |
Calcification volume (mm3) | 1213.4 ± 149.1 | 1129.3 ± 154 | 1261.8 ± 123 | < 0.001 |